ArticleJournal of medical case reports2026
Sustained complete remission with third-line nivolumab in advanced renal cell carcinoma: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal cell carcinoma is a challenging malignancy that often necessitates advanced systemic therapies. Immunotherapy with checkpoint inhibitors has emerged as a cornerstone for managing advanced renal cell carcinoma. This case highlights the clinical course, treatment response, and management of complications in a patient with advanced renal cell carcinoma treated with immunotherapy. CASE PRESENTATION: A 51-year-old white male patient presented with dizziness, leading to a diagnosis of advanced renal cell carcinoma involving a large left renal mass, pulmonary metastases, and retroperitoneal lymphadenopathy. After radical nephrectomy in 2016, histopathology confirmed T3a clear cell carcinoma with vascular invasion. Initial systemic treatment included targeted therapy with sunitinib, followed by axitinib owing to disease progression. Nivolumab, a programmed death-1 inhibitor, became available in Hungary in 2018 and was initiated as third-line therapy in mid-2018. The patient has remained disease-free without any therapy for the past 27 months, with follow-up imaging through September 2025 confirming sustained complete remission first documented in October 2020, amounting to nearly 5 years of continuous complete remission. The patient experienced manageable immune-related adverse events, including nephritis and colitis, which were treated with corticosteroid therapy. Routine imaging and clinical assessments confirmed no evidence of recurrence as of September 2025. This case underscores the efficacy and durability of immune checkpoint inhibitors in advanced renal cell carcinoma.
conclusionThis case exemplifies the long-term benefit of immunotherapy in advanced renal cell carcinoma, emphasizing the importance of vigilant monitoring for immune-related adverse events, sustained follow-up, and the potential for extended therapy-free remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.